If you're taking a GLP-1 medication like semaglutide or tirzepatide for diabetes or weight loss, your eye doctor needs to know about it. These medications have skyrocketed in use over the past five years, with prescriptions jumping 350% between 2019 and 2024, driven mainly by semaglutide and tirzepatide. About 43% of patients with type 2 diabetes have either actively taken or are currently taking a GLP-1 agonist, according to a 2024 survey. But as these drugs have become mainstream, eye care professionals are uncovering a critical safety concern that many patients don't know about. What Are GLP-1 Drugs and Why Are They So Popular? GLP-1 receptor agonists work by mimicking hormones your gut naturally produces when you eat food. These medications slow down how quickly food moves from your stomach to your small intestine, which makes you feel fuller longer and helps control blood sugar spikes. The drugs are prescribed for type 2 diabetes patients whose hemoglobin A1C (a measure of average blood sugar over three months) is greater than 8.5%, as well as for weight loss in people with a body mass index (BMI) of 30 or higher, or those with a BMI above 27 who have weight-related conditions like high blood pressure or sleep apnea. Several GLP-1 medications are now available on the market, each with different strengths and approval dates. Semaglutide, marketed as Ozempic for diabetes and Wegovy for weight loss, was approved by the FDA in 2017 and 2021 respectively. Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, received FDA approval in 2022 and is unique because it acts as a "twincretin," meaning it mimics two different incretin hormones rather than just one. In clinical trials, tirzepatide proved more effective than semaglutide at lowering A1C levels, with patients achieving a 2.01% reduction compared to 1.86% on the highest dose of semaglutide after 40 weeks. What Eye Complications Are Doctors Discovering? The concern about GLP-1 medications and eye health first emerged from a major clinical trial called SUSTAIN-6, which studied semaglutide for diabetes. The study found that patients taking semaglutide had a higher risk of worsening diabetic retinopathy, a condition where high blood sugar damages blood vessels in the eye. However, researchers noted that most patients who developed complications already had some degree of retinopathy at the start of the study, making it difficult to draw firm conclusions about the medication's direct effect. More recent research published in 2025 in the journal Diabetologia examined whether GLP-1 drugs worsen retinopathy in patients who had no retinopathy or only mild nonproliferative diabetic retinopathy (NPDR) at the time they started treatment. This distinction matters because it helps doctors understand whether the medication itself causes problems or simply accelerates existing eye disease. The findings suggest that patients with pre-existing retinopathy may face increased risk when starting GLP-1 therapy, particularly if they experience rapid improvements in their blood sugar control. How to Protect Your Eyes While Taking GLP-1 Medications - Schedule a baseline eye exam: Before starting a GLP-1 medication, have your eye doctor perform a comprehensive exam to document your current retinal health and establish a baseline for comparison. - Inform your eye doctor about your medication: Tell both your primary care doctor and eye care professional that you're taking a GLP-1 drug, including the specific medication name and dosage, so they can monitor you appropriately. - Plan for regular follow-up appointments: Patients with moderate NPDR or higher should be seen by their eye doctor at least once every three to six months after starting GLP-1 treatment to check for any progression of retinopathy. - Report vision changes immediately: Contact your eye doctor right away if you notice floaters, blurred vision, dark spots, or any other changes in your eyesight while taking these medications. - Discuss rapid blood sugar improvements: If your blood sugar control improves very quickly after starting a GLP-1 drug, mention this to your eye doctor, as faster improvements may carry higher risk for retinopathy progression. Who Faces the Highest Risk? Not everyone taking a GLP-1 medication faces the same level of eye risk. Patients at higher risk for developing or worsening diabetic retinopathy include those with a higher A1C level at baseline, those who have had diabetes for a longer time, and those who experience significant A1C reductions after starting treatment. If you fall into any of these categories, your eye doctor may recommend more frequent monitoring or additional imaging to catch any changes early. It's also important to note that GLP-1 medications have other common side effects unrelated to eye health. About 15% to 45% of patients experience nausea and vomiting because of how these drugs slow stomach emptying, a process called gastroparesis. This is why doctors exercise caution when prescribing GLP-1 drugs to patients who already have pre-existing gastroparesis, which is common in people with type 2 diabetes. Why Is This Information Critical Right Now? The surge in GLP-1 prescriptions means millions of people are now taking these medications without fully understanding the potential eye complications. The FDA shortage of semaglutide from 2022 to February 2025 and tirzepatide from 2022 to December 2024 led to expanded access through compounding pharmacies, which further increased the number of people using these drugs. As more patients start treatment, eye doctors are seeing an uptick in cases where retinopathy worsens shortly after GLP-1 initiation, prompting the medical community to develop better screening and monitoring protocols. The bottom line is straightforward: GLP-1 medications are powerful tools for managing type 2 diabetes and weight loss, but they require careful eye health monitoring. If you're considering starting one of these medications or are already taking one, make sure your eye doctor knows about it. Regular eye exams and open communication between your diabetes care team and eye care team can help catch any problems early and keep your vision protected while you benefit from these increasingly popular treatments.
